Phase I study of a candidate vaccine based on recombinant HIV-1 gp160 (MN/LAI) administered by the mucosal route to HIV-seronegative volunteers: the ANRS VAC14 study.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples